Summary
This prediction ended on 12.11.23 with a price of €17.60. With a performance of -7.37%, the BUY prediction for Evotec SE by Maxfloh closed slightly in the red. This prediction was marked as speculative and is excluded from Maxfloh's performance statistics.Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Evotec SE | -3.233% | -3.233% | -64.953% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
According to Maxfloh what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Cons
Comments by Maxfloh for this prediction
In the thread Evotec AG diskutieren